Raw Raloxifene powder Marketing.
Raloxifene- for women who have been through the menopause.
Raloxifene is another option for some women with osteoporosis.
If Raloxifene is stopped, your doctor
will tell you when to start taking Raloxifene again after your surgery or procedure.
However, there are other medications(such as Raloxifene, bisphosphonates including alendronate)
that are also effective in preventing bone loss and may be safer.
In this trial, which studied almost 20,000 women, Raloxifene had fewer side effects than tamoxifen,
though it did permit more DCIS to form.
Raloxifene cannot be used to treat invasive breast cancer
or to prevent invasive breast cancer from coming back in women who have already had the condition.
In particular, Raloxifene serves as an Estrogen antagonist in breast tissue
and uterine tissue while at the same time acting as an Estrogen agonist in bone tissue.
There are medicines(tamoxifen and Raloxifene) which have also been shown
to reduce the risk of breast cancer in women who are at increased risk of the disease.
Considering these properties, it is therefore understandable why Raloxifene had demonstrated some clear advantages over Nolvadex,
and has proven itself as a novel new drug in the treatment of various post-menopausal diseases in female patients.
In 2006, the large STAR clinical study concluded that Raloxifene is equally effective in reducing the incidence of breast cancer,
but after an average 4-year follow-up there were 36% fewer uterine cancers and 29% fewer blood clots in women taking Raloxifene than in women taking tamoxifen, although the difference was not statistically significant.
In 2006, the large STAR clinical study concluded that Raloxifene is equally effective in reducing the incidence of breast cancer,
but after an average 4-year follow-up, although the difference was not statistically significant, there were 36% fewer uterine cancers and 29% fewer blood clots in women taking Raloxifene than in women taking tamoxifen.